Potential Cost Savings With Low-Dose Abiraterone in the United States

JCO Glob Oncol. 2020 May:6:743-744. doi: 10.1200/GO.20.00140.

Authors

Naveen Premnath¹, Ramy Sedhom¹, Arjun Gupta¹

Affiliation

¹ Naveen Premnath, MD, University of Texas Southwestern Medical Center, Dallas, TX; and Ramy Sedhom, MD and Arjun Gupta, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.

No abstract available

Publication types

Letter
Comment

MeSH terms

Androstenes* / adverse effects
Cost Savings
Humans
Male
Prostatic Neoplasms*
United States

Substances

Androstenes
abiraterone